Dana-farber-cancer Institute Inc.

Jounce Therapeutics, Inc.

Christopher Harvey

Glenn Dranoff

Kai W Wucherpfennig

F Stephen Hodi

Bettina Franz

Kenneth F May, Jr

Sriram Sathyanarayanan

Stephen Sazinsky

Jennifer S Michaelson

Kutlu Goksu Elpek

Heather Hirsch

Jason Windham Reeves

Igor Feldman

Kenneth May

Amanda Elizabeth Hanson

Martin Yu Fan

Lauren Pepper MacKenzie

Deborah Law

Amit Deshpande

The invention provides methods of treating cancer and methods for selecting treatment approaches for cancer.

Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist

Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.

Gene signatures for determining ICOS expression

The present disclosure provides, in part, compositions comprising peptides that immunospecifically bind to a defined binding partner, such as MHC class I polypeptide-related sequence A (MICA), or an epitope thereon. In some embodiments, the peptides comprise one or more complementarity determining regions relating to the complementarity regions shown in Table 1. The disclosure also provides methods of treating cancer in a subject using the compositions disclosed herein, and methods of isolating human antibodies from cancer patients following immunotherapy.

Therapeutic peptides

The present disclosure provides, in part, compositions comprising peptides immuno specifically binds to defined binding partners, wherein the peptides comprise at least complementarity determining regions relating to the complementarity regions shown in Table 1.

The present invention provides compositions and methods for treating cancer in a subject by eliciting an immune response against a MIC polypeptide.

Vaccine compositions and methods for restoring NKG2D pathway function against cancers

The present disclosure provides, in part, compositions comprising peptides immunospecifically binds to MHC class I polypeptide-related sequence A (MICA).

Antibodies that bind to MHC class I polypeptide-related sequence A

The present disclosure provides, in part, compositions comprising an antibody or antibody fragment that immunospecifically binds to MCH class I polypeptide-related sequence A (MICA), or an epitope thereof.

Growing community of inventors

Boston, MA, United States of America

Christopher Harvey